Aurobindo Pharma Ltd Financials
Company Logo

Aurobindo Pharma Ltd Financial Statement

Aurobindo Pharma Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Jun 2024
Revenue2525.41
Operating Expense1961.16
Net Profit329.04
Net Profit Margin13.03
Earning Per Share5.62
EBIDTA566.71
Effective Tax Rate21.21

Aurobindo Pharma Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual10,645.64
Operating Expenses Annual8,421.60
Operating Profit Annual2,894.14
Interest Annual182.60
Depreciation236.72
Net Profit Annual1,900.10
Tax Annual502.82

Aurobindo Pharma Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning357.13
Cash Flow from Operations1,714.80
Cash Flow from Investing-151.58
Cash Flow from Financing-1,837.03
Cash Flow at the End83.32

Aurobindo Pharma Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)27.19
PBIT Margin (%)24.79
PBT Margin (%)24.65
Net PROFIT Margin (%)18.36
Return On Networth / Equity (%)10.35
Return On Networth /Employed (%)11.74
Return On Assets (%)8.63
Total Debt / Equity (X)0.19
Asset Turnover Ratio (%)0.47

Aurobindo Pharma Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual2,419.13
Total Current Assets Annual7,239.13
Non Current Assets Annual17,914.85
Total Shareholders Funds Annual19,722.82
Total Assets Annual25,153.98

Aurobindo Pharma Ltd Earning Calls

EPS (INR)

Expected

15.69

Reported

15.69

Surprise

0.00%

Mar 2024

EPS beaten by 0.00%

Dec 2023

EPS beaten by 0.00%

Sep 2023

EPS beaten by 0.38%

Get Your FAQs Right

As of Sep 18, 2024, Aurobindo Pharma Ltd has a market capitalization of 63,835.08 Cr. Value Research classifies it as a Large-Cap company.
Yes, Aurobindo Pharma Ltd is debt-free with a debt-to-equity ratio of 0.14.
In FY 2023 , Aurobindo Pharma Ltd recorded a total revenue of approximately 10,542.21 Cr marking a significant milestone in the company's financial performance.
Aurobindo Pharma Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.2% and -0.0% annually, respectively..
Aurobindo Pharma Ltd's current PE ratio is 32.67.
Aurobindo Pharma Ltd's ROCE averaged 9.3% from the FY ending March 2022 to 2024, with a median of 8.7%. It peaked at 11.7% in March 2024, reflecting strong capital efficiency over the period..
Aurobindo Pharma Ltd's latest EBIT is Rs. 2,639.56 Cr, surpassing the average EBIT of Rs. 1,994.83 Cr over the 5 years..